Health Canada accepts Paladin’s NDS for epilepsy-linked seizure therapy
Discovered by SK Biopharmaceuticals and SK life science, cenobamate is a new small molecule anti-seizure therapy.
Company News
Latest in
Company News
Sartorius to acquire UK’s Albumedix for $501.5m
With the acquisition, Albumedix will become part of the Bioprocess Solutions Division of Sartorius.
Pfizer signs agreement to acquire biopharma firm GBT for $5.4bn
GBT takeover complements and boosts Pfizer’s expertise in rare haematology.
US FDA grants approval for Orion-Bayer’s Nubeqa combo for prostate cancer
The darolutamide combination treatment substantially lowered mortality risk by 32.5% in mHSPC patients.
AstraZeneca-Daiichi Sankyo’s Enhertu gets US FDA approval for breast cancer
The approval was based on findings from the Phase III DESTINY-Breast04 trial of Enhertu.
US FDA approves Pfizer-Myovant’s Myfembree for endometriosis pain
The companies will co-market the drug in the region and will be made available soon.
EC grants approval for Merck-AstraZeneca’s Lynparza for breast cancer
The approval was based on the Phase III OlympiA clinical trial of Lynparza versus placebo.
Amgen to acquire biopharma firm ChemoCentryx for $3.7bn
The board of directors of Amgen and ChemoCentryx has granted unanimous approval for the acquisition.